Comparison of methods for estimating drug coverage for filariasis elimination, Leogane Commune, Haiti

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 97, Issue 5, 2003, Pages 501-505

  Mathieu, Els ^a,b   Deming, Michael ^b   Lammie, Patrick J ^b   McLaughlin, Steven I ^b   Beach, Michael J ^b   Deodat, Domingue J ^c   Addiss, David G ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c Hopital Sainte Croix   (Haïti)

Author keywords

Albendazole; Community based distribution; Cost analysis; Diethylcarbamazine; Haiti; Lymphatic filariasis; Survey methods

Indexed keywords

ALBENDAZOLE; ANTIFILARIAL AGENT; DIETHYLCARBAMAZINE; IVERMECTIN;

ARTICLE; CHILD; CLUSTER ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG MONITORING; FILARIASIS; FREQUENCY ANALYSIS; HAITI; HEALTH SURVEY; HUMAN; INTERMETHOD COMPARISON; LYMPHATIC SYSTEM INFECTION; MAJOR CLINICAL STUDY; PRIMARY SCHOOL; PROBABILITY; SAMPLING; ADULT; AGE DISTRIBUTION; AGED; COMPARATIVE STUDY; DRUG COMBINATION; ECONOMICS; ELEPHANTIASIS; INFANT; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ALBENDAZOLE; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DIETHYLCARBAMAZINE; DRUG THERAPY, COMBINATION; ELEPHANTIASIS, FILARIAL; FILARICIDES; HAITI; HUMANS; INFANT; INFANT, NEWBORN; IVERMECTIN; MIDDLE AGED;

EID: 7244245522     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-9203(03)80006-8     Document Type: Article

References (14)

1. Beach M.J. Streit T.G. Addiss D.G. Prospere R. Roberts J.M. & Lammie P.J. Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitianschoolchildren American Journal of Tropical Medicine and Hygiene 60 1999 479-486
2. Brogan D. Flagg E.W. Deming M. & Waldman R. Increasing the accuracy of the expanded programme on immunization's cluster survey design Annals of Epidemiology 4 1994 302-311
3. Haddix A.C. & Kestler A. Lymphatic filariasis: Economic aspects of the disease and programmes for its elimination Transactions of the Royal Society of Tropical Medicine and Hygiene 94 2000 592-593
4. Kish L. Survey Sampling 1995 John Wiley & Sons New York
5. Michael E. Bundy D.A. & Grenfell B.T. Reassessing the global prevalence and distribution of lymphatic filariasis Parasitology 112 1996 409-428
6. Ndyomugyenyi R. & Remme J. Using ivermectin-treatment coverage among schoolchildren monitored by schoolteachers as a proxy of population coverage in areas of Uganda whereonchocerciasis is endemic Annals of Tropical Medicine and Parasitology 96 2002 53-60
7. Ottesen E.A. The global programme to eliminate lymphatic filariasis Tropical Medicine and International Health 5 2000 591-594
8. Ottesen E.A. Duke B.O. Karam M. & Behbehani K. Strategies and tools for the control/elimination of lymphatic filariasis Bulletin of the World Health Organization 75 1997 491-503
9. Ottesen E.A. Ismail M.M. & Horton J. The role of albendazole in programmes to eliminate lymphatic filariasis Parasitology Today 15 1999 382-386
10. UNICEF Monitoring Progress Towards the Goals of the World Summit for Children. A Practical Handbook for Multiple-indicator Surveys 1995 UNICEF New York
11. WHO Training for Mid-level Managers 1991 World Health Organization Geneva WHO/EPI/MLM/91.10
12. WHO The World Health Report 1995 - Bridging the Gaps 1995 World Health Organization Geneva
13. WHO Preparing and Implementing a National Plan to Eliminate Lymphatic Filariasis 2000 World Health Organization Geneva WHO/CDS/CPE/CEE/2000.15
14. WHO Lymphatic filariasis Weekly Epidemiological Record 76 2001 149-156